Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Intravenous Doses of LIS1 in Kidney Transplanted Patients

Next Previous
Search
Trial Profile

First in Human Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Intravenous Doses of LIS1 in Kidney Transplanted Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LIS 1 (Primary) ; Methylprednisolone; Mycophenolic acid; Steroids; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Xenothera

    • Most Recent Events

    • 16 Aug 2022 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2022 According to a Xenothera media release, results from this trial were presented at the American Transplant Congress (ATC) 2022.
    • 09 Jun 2022 Results published in the Xenothera Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top